CD300a/LMIR1 Antibody (232612) [Alexa Fluor™ Plus 488]

• Reactivity: Hu
• Clone: 232612
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor Plus 488

CD300a/LMIR1 Antibody (232612) [Alexa Fluor™ Plus 488] Summary

• Specificity: Detects human CD300a/LMIR1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross‑reactivity with recombinant human LMIR2 (CMRF-35A) is observed and no cross-reactivity with recombinant human LMIR3, 4, 5, or 6 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD300a/LMIR1 Antibody (232612) [Alexa Fluor™ Plus 488]

• CD300a antigenCMRF35H9
• CD300a molecule
• CD300a
• CLM8
• CLM-8
• CMRF35H leukocyte immunoglobulin-like receptor
• CMRF-35H
• CMRF35-H
• CMRF35-H9
• CMRF-35-H9CD300 antigen-like family member A
• CMRF35HIRp60
• CMRF35-like molecule 8
• IGSF12
• IGSF12NK inhibitory receptor
• Immunoglobulin superfamily member 12
• Inhibitory receptor protein 60
• IRC1
• IRC1/IRC2
• IRC2
• IRp60
• leukocyte membrane antigen
• LMIR1
• MAIR-I
• Mcipr1
• NKRL
• Pigr4

Background

CD300a, also known as LMIR1 (in rodents), CMRF-35H, IRp60, CLM-8, and MAIR-I, is a 60 kDa glycoprotein member of the immunoglobulin superfamily (1). Human CD300a consists of a 163 amino acid (aa) extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane segment, and a 98 aa cytoplasmic domain that contains three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and a non-canonical ITIM (2). Alternative splicing may generate additional isoforms that either lack the Ig-like domain or contain only the cytoplasmic domain. Within the ECD, human CD300a shares 40% and 43% aa sequence identity with mouse and rat LMIR1, respectively. In human, CD300a is expressed on peripheral blood eosinophils, mast cells, neutrophils, plasmacytoid dendritic cells, and various T cell subsets (3‑7). Antibody crosslinking of CD300a induces phosphorylation of tyrosine residues in the cytoplasmic domain. This leads to the recruitment of phosphatases SHIP, SHP-1, and SHP-2 and inhibition of NK cell, eosinophil, and mast cell activation (2, 3, 5‑7). Crosslinking of CD300a to other surface proteins such as SCF R or Fc epsilon RI on mast cells, Fc gamma RIIA on neutrophils, or CCR3 on mast cells and eosinophils inhibits downstream signaling from those receptors (5, 10‑12). CD300a crosslinking also limits the in vivo activities of these cells with a subsequent reduction of allergic inflammation symptoms (4, 11, 12).

1. Clark, G.J. et al. (2009) Trends Immunol. 30:209.
2. Cantoni, C. et al. (1999) Eur. J. Immunol. 29:3148.
3. Munitz, A. et al. (2006) Blood 107:1996.
4. Bachelet, I. et al. (2005) J. Immunol. 175:7989.
5. Alvarez, Y. et al. (2008) Mol. Immunol. 45:253.
6. Ju, X. et al. (2008) Blood 112:1184.
7. Clark, G.J. et al. (2007) J. Leukoc. Biol. 82:1126.
8. Kumagai, H. et al. (2003) Biochem. Biophys. Res. Commun. 307:719.
9. Yotsumoto, K. et al. (2003) J. Exp. Med. 198:223.
10. Bachelet, I. et al. (2008) J. Immunol. 180:6064.
11. Bachelet, I. et al. (2006) J. Allergy Clin. Immunol. 117:1314.
12. Munitz, A. et al. (2006) J. Allergy Clin. Immunol. 118:1082.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.